Pay in 4 interest-free payments of $6.61 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Methods Study design An 8-week randomized, double-blind, placebo-controlled parallel study was conducted at a single center, KGK Synergize Inc., in London, ON, Canada, between January 12, 2015 and June 19, 2015
Key details regarding the July 2026 review: July 23, 2026 Review: BPC-157 (wound/injury), KPV (inflammation), TB-500 (wound healing), and MOTs-C (obesity/osteoporosis)
Component-Level Trial Findings CJC-1295 (without DAC, modified GRF 1-29) Phase 1 and Phase 2 work described: Dose-dependent GH elevation (2-10x baseline at studied doses, PMID 16352683) IGF-1 elevation of 1.5-3x baseline at 1-2 weeks Mild facial flushing post-injection in some participants No serious adverse events at studied doses CJC-1295 with DAC The DAC-modified version covalently binds to albumin, extending half-life to 5-8 days (PMID 16352683)
The recommendation is to take a single pill 3 days before the onset and continue taking the same pill for the no of days you would like to delay your periods
Epimedin B Epimedin B is one of the main flavonoid components of Epimedium brevicornum Maxim., a traditional Chinese medicainal herb
